Comparison · NCT01639872-sae
Clozapine vs Risperidone: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Clozapine vs Risperidone: serious adverse events. Trial comparisons, record NCT01639872-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01639872-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.13 | 0.0454 | 0.321 | wilson | |
| Risk in group 2 | 0.125 | 0.0434 | 0.31 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00543 | -0.198 | 0.213 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.04 | 0.234 | 4.65 | log | |
| Odds ratio, group 1 over group 2 | 1.05 | 0.189 | 5.83 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Clozapine than on Risperidone | 184 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Clozapine | The blinded CLOZ will be titrated on a recommended standard schedule, supervised by a study physician (or other prescriber) who can make the necessary adjustments to account for symptom control and tolerability. The titration is recommended to begin at 12.5 mg and then increase while the open-label base antipsychotic is tapered with a recommended goal of decreasing the base antipsychotic by 25% each week. If clinically tolerated, the target dose of CLOZ is 400 mg/day.~Clozapine: Clozapine: target dose of 400mg per day with a maximum dose of 550mg per day | 3 | 23 | EG000 |
| Group 2 | Risperidone | The blinded RISP will also be titrated in the first weeks, using a titration schedule, with a target dose of 4 mg/day, while the open label base antipsychotic is tapered in a similar fashion.~Risperidone: Clozapine: target dose of 4mg per day with a maximum dose of 6mg per day | 3 | 24 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 6 months
Source ClinicalTrials.gov
Trial
- Title
- Clozapine for Cannabis Use in Schizophrenia
- NCT number
- NCT01639872
- Phases
- PHASE4
- Conditions
- Schizophrenia, Cannabis Abuse, Cannabis Dependence, Dual Diagnosis
- Interventions
- Clozapine, Risperidone
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Results first posted
- 2019-12-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01639872?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01639872-sae